Capricor reports $42.7M Q3 loss amid deramiocel launch preparations

Capricor reported a net loss of $42.7 million, or $0.73 per share, for the third quarter of 2026, compared to a net loss of $24.6 million, or $0.54 per share, in the prior period, according to Motley Fool.

The increased loss reflects higher precommercial activities and manufacturing scale-up expenses as the company prepares for a potential commercial launch of deramiocel, a treatment nearing FDA decision.

Operating expenses rose to $44.7 million for the quarter, up from $26.3 million, driven primarily by these preparations.

Capricor's cash and marketable securities totaled $198.5 million as of September 30, 2026, which management stated is sufficient to fund operating capital requirements for at least 12 months.

Clinical data from the HOPE-3 trial showed a 76% slowing of disease progression in patients switching from placebo to deramiocel, with a 0.5 point decline compared to 2.0 points during the placebo year.

Additionally, the HOPE-3 primary endpoint demonstrated a 1.1 point absolute difference in the Performance of the Upper Limb scale versus placebo, which management described as clinically meaningful.